TITLE

Endogenous endophthalmitis in a rheumatoid patient on tumor necrosis factor alpha blocker

AUTHOR(S)
Agarwal, Pankaj Kumar; Gallaghar, Mick; Murphy, Elizabeth; Virdi, Meena
PUB. DATE
May 2007
SOURCE
Indian Journal of Ophthalmology;May2007, Vol. 55 Issue 3, p230
SOURCE TYPE
Academic Journal
DOC. TYPE
journal article
ABSTRACT
The development of anti-tumor necrosis factor (TNF) therapies is a milestone in the therapy of rheumatic diseases. It is of concern whether all potential undesired complications of therapy have been evaluated within clinical trials which have led to treatment approval. Specialists prescribing TNF blockers should be aware of the unusual and severe complications that can occur. We describe a case of endogenous endophthalmitis in a rheumatoid patient on TNF alpha blocker.
ACCESSION #
24895683

 

Related Articles

  • Rheumatoid arthritis - treatment. Nishikawa, Masataka; Owaki, Hajime; Fuji, Takeshi // Rheumatology;Apr2011 Supplement 3, Vol. 50 Issue suppl_3, piii111 

    Background: In Japan, more than 20 rheumatoid arthritis (RA) patients died of interstitial pneumonia (IP) caused by leflunomide (LEF) were reported, but many of them were considered as the victims of opportunistic infection currently. In this paper, efficacy and safety of low-dose LEF classified...

  • Biological Disease Modifying Anti-Rheumatic Drugs. Cranwell-Bruce, Lisa A. // MEDSURG Nursing;May/Jun2011, Vol. 20 Issue 3, p147 

    No abstract available.

  • Treat-to-target: a tailored treatment approach to rheumatoid arthritis. Palmer, Deborah; El Miedany, Yasser // British Journal of Nursing;3/28/2013, Vol. 22 Issue 6, p308 

    In contrast to articles and books written about rheumatoid arthritis (RA) two or more decades ago that largely focused on 'coping' with the disease, there have been significant developments in the treatment of RA over the past 10 years. Patients can now be diagnosed and treated and expect to...

  • Immunogenicity of biologic agents in rheumatoid arthritis patients: lessons for clinical practice. Schaeverbeke, Thierry; Truchetet, Marie-Elise; Kostine, Marie; Barnetche, Thomas; Bannwarth, Bernard; Richez, Christophe // Rheumatology;Feb2016, Vol. 55 Issue 2, p210 

    Anti-drug antibodies (ADAbs) develop in up to a third of patients treated with biologic agents, with such immunogenicity being one of the main reasons for the loss of efficacy observed in an important proportion of patients treated with such agents. The appearance of ADAbs has consequences in...

  • Terapia biológica en enfermedades reumatológicas. Usarte-Gil, Manuel F.; Acevedo-Vásquez, Eduardo M.; Alarcón, Graciela S. // Revista Medica Herediana;abr-jun2013, Vol. 24 Issue 2, p141 

    The advent of biologic therapies in Rheumatology has modified significantly the prognosis of patients with rheumatoid arthritis (RA), juvenile arthritis (JA), ankylosing spondylitis (AS), among others. In contrast to the conventional therapies, these biological therapies are directed at specific...

  • Disease-Modifying Antirheumatic Drugs and Risk for Developing Diabetes.  // Primary Care Reports;Sep2011 Supplement, p18 

    The article offers information on a study that examined rheumatoid arthritis and severe psoriasis patients who began treatment with a disease-modifying antirheumatic drugs in the U.S. and Canada.

  • Aggressive therapy in patients with early arthritis results in similar outcome compared with conventional care: the STREAM randomized trial. van Eijk, Izhar C.; Nielen, Markus M. J.; van der Horst-Bruinsma, Irene; Tijhuis, Gerard J.; Boers, Maarten; Dijkmans, Ben A. C.; van Schaardenburg, Dirkjan // Rheumatology;Apr2012, Vol. 51 Issue 4, p686 

    Objective. To compare the effects of aggressive tight control therapy and conventional care on radiographic progression and disease activity in patients with early mild inflammatory arthritis.Methods. Patients with two to five swollen joints, Sharp–van der Heijde radiographic score (SHS)...

  • Rheumatoid arthritis and pregnancy: evolution of disease activity and pathophysiological considerations for drug use. Hazes, Johanna M.W.; Coulie, Pierre G.; Geenen, Vincent; Vermeire, Séverine; Carbonnel, Franck; Louis, Edouard; Masson, Pierre; De Keyser, Filip // Rheumatology;Nov2011, Vol. 50 Issue 11, p1955 

    It has long been known that pregnancy and childbirth have a profound effect on the disease activity of rheumatic diseases. For clinicians, the management of patients with RA wishing to become pregnant involves the challenge of keeping disease activity under control and adequately adapting drug...

  • Mavrilimumab: an evidence based review of its potential in the treatment of rheumatoid arthritis. Di Franco, Manuela; Gerardi, Maria Chiara; Lucchino, Bruno; Conti, Fabrizio // Core Evidence;2014, Vol. 9, p41 

    Rheumatoid arthritis (RA) management has greatly improved with the development of biologic disease modifying antirheumatic drugs, but a proportion of patients do not improve despite the biologic drugs currently available. We need new biologic agents with novel mechanisms of action for the...

  • Inhibition of TNFα does not induce viral reactivation in patients with chronic hepatitis C infection: two cases. Aslanidis, S.; Vassiliadis, T.; Pyrpasopoulou, A.; Douloumpakas, I.; Zamboulis, C. // Clinical Rheumatology;Feb2007, Vol. 26 Issue 2, p261 

    Chronic infections, such as hepatitis C, in the setting of rheumatic disorders pose a potential hindrance to optimal management because of possible complications linked to the institution of immune suppression, as well as the high incidence of hepatotoxicity associated with many of the...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics